Extended panel of biomarkers for long term monitoring of effectiveness of 3 direct antiviral regimen in HCV genotype 1b infection: results from a Romanian infectious disease hospital

1. Blonski W, Reddy KR. Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis 2008;12:661–74. DOI: 10.1016/j.cld.2008.03.00710.1016/j.cld.2008.03.00718625433Search in Google Scholar

2. Stanciu C, Trifan A. Hepatitis C Virus Treatment Revolution: Eastern European Story Hepat Mon 2015;15(7):e28969. DOI: 10.5812/hepatmon.28969v210.5812/hepatmon.28969v2453973126300932Search in Google Scholar

3. Hilgenfeldt EG, Schlachterman A, Firpi RJ. Hepatitis C: Treatment of difficult to treat patients. World J Hepatol 2015;7(15):1953–63. DOI: 10.4254/wjh.v7.i15.195310.4254/wjh.v7.i15.1953451715426244069Search in Google Scholar

4. Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol 2018;69(3):718–35. DOI: 10.1016/j.jhep.2018.05.01110.1016/j.jhep.2018.05.01129777749Search in Google Scholar

5. Viekirax® (AbbVie). Rezumatul caracteriticilor produsului [online]. [2015] [cited 2019 December 9]; Available from: URL: https://www.ema.europa.eu/en/documents/product-information/viekirax-epar-product-information_ro.pdfSearch in Google Scholar

6. Exviera® (AbbVie). Rezumatul caracteriticilor produsului [online]. [2015] [cited 2019 December 9]; Available from: URL: https://www.ema.europa.eu/en/documents/product-information/exviera-epar-product-information_ro.pdfSearch in Google Scholar

7. Protocol terapeutic corespunzator DCI Ombitasvirum + Paritaprevirum + Ritonavirum + DCI Dasabuvirum [online]. [2015] [cited 2019 December 9]; Available from: URL: http://www.cnas.ro/page/tratament-fara-interferon-3.htmlSearch in Google Scholar

8. Streinu-Cercel A. Hepatitis C burden in Romania 2016–2017 Evaluation 2018 challenges [online]. [cited 2019 December 9]; Available from: URL: http://www.vhpb.org/files/html/Meetings_and_publications/Presentations/BUCH32.pdfSearch in Google Scholar

9. Covic A, Iancu LS, Apetrei C, Scripcaru D, Volovat C, Mititiuc LI et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999;14:40–5. DOI: 10.1093/ndt/14.1.4010.1093/ndt/14.1.4010052474Search in Google Scholar

10. Gheorghe L, Iacob S, Csiki IE. Prevalence of hepatitis C in Romania. Different from European rates. J Hepatol 2008;49:658–63. DOI: 10.1016/j.jhep.2008.06.01610.1016/j.jhep.2008.06.01618684541Search in Google Scholar

11. Voiculescu M, Iliescu L, Ionescu C, Micu L, Ismail G, Zilisteanu D et al. A Cross-Sectional Epidemiological Study of HBV, HCV, HDV and HEV Prevalence in the SubCarpathian and South-Eastern Regions of Romania. J Gastrointestin Liver Dis 2010; 19(1):43–8.Search in Google Scholar

12. European Centre for Disease Prevention and Control. Hepatitis C. In: ECDC. Annual epidemiological report for 2016 [online]. [2018] [cited 2019 December 9]; Available from: URL: https://www.ecdc.europa.eu/en/publications-data/hepatitis-c-annual-epidemiological-report-2016Search in Google Scholar

13. Popovici O, Molnar GB, Popovici F, Janţă D, Pistol A, Azoicăi D. A Seroprevalence Study of Hepatitis B and C Virus Infections in a Hospitalized Population in Romania, an Opportunity for a Better National Prevention and Control Strategy. J Gastrointestin Liver Dis 2016;25(1):25–32. DOI: 10.15403/jgld.2014.1121.251. hbc10.15403/jgld.2014.1121.251Search in Google Scholar

14. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31(2):30–60. DOI: 10.1111/j.1478-3231.2011.02539.x10.1111/j.1478-3231.2011.02539.x21651702Search in Google Scholar

15. Ahmed H, Abushouk AI, Menshawy A, Mohamed A, Negida A, Loutfy SA et al. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis. Clin Drug Investig 2017;37(11):1009–23. DOI: 10.1007/s40261-017-0565-510.1007/s40261-017-0565-528871475Search in Google Scholar

16. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973–82. DOI: 10.1056/NEJMoa140286910.1056/NEJMoa140286924725237Search in Google Scholar

17. Trifan A, Stanciu C, Gheorghe L, Iacob S, Curescu M, Cijevschi Prelipcean C et al. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine 2017;96(50):e9271. DOI: 10.1097/MD.000000000000927110.1097/MD.0000000000009271Search in Google Scholar

18. Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A et al. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol 2017;2:427–34. DOI: 10.1016/S2468-1253(17)30048-110.1016/S2468-1253(17)30048-1Search in Google Scholar

19. Danilau D, Malich N, Litvinchuk D, Karpov I. Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus. Clin Exp Hepatol 2017;3(3):164–68. DOI: 10.5114/ceh.2017.7028110.5114/ceh.2017.70281Search in Google Scholar

20. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New England J Med 2014;370:1604–14. DOI: 10.1056/NEJMoa140156110.1056/NEJMoa1401561Search in Google Scholar

21. Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study. Clin Infect Dis 2015;60:608−10. DOI: 10.1093/cid/ciu86510.1093/cid/ciu865Search in Google Scholar

22. Calleja JL, Rincon D, Ruiz-Antoran B, Sacristan B, Perello C, Lens S et al. Effectiveness and safety of ombitasvir and paritaprevir, ritonavir and dasabuvir patients with genotype 1 chronic hepatitis C virus infection: results from Spanish real world cohort. J Hepatol 2016; 64(2):218–19. DOI: 10.1016/S0168-8278(16)00189-610.1016/S0168-8278(16)00189-6Search in Google Scholar

23. Agarwal K, Gaeta GB, Lee SS, Dumas EO, A Streinu-Cercel, E Schote et al. Long-term clinical outcomes in HCV genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: First interim safety and efficacy results from TOPAZ-I [online]. [2016] [cited 2019 December 9]; Available from: URL: http://www.natap.org/2016/AASLD/AASLD_54.htmSearch in Google Scholar

24. Preda CM, Popescu CP, Baicus C, Voiosu TA, Manuc M, Pop CS et al. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis. Liver Int 2018;38(4):602–10. DOI: 10.1111/liv.1355010.1111/liv.1355028816020Search in Google Scholar

25. Dinu S, Țârdei G, Ceauşu E, Florescu SA, Micu L, Ecobici AM et al. Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania. Rev Romana Med Lab. 2018;26(4):443–9. DOI: 10.2478/rrlm-2018-002910.2478/rrlm-2018-0029Search in Google Scholar